Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial
<p><strong>Background:</strong><br /> Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.</p><br /> <p><strong>Method:</strong>...
Main Authors: | , , , , , , , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2020
|
_version_ | 1797107748118200320 |
---|---|
author | Steel, C Korrelboom, K Fazil Baksh, M Kingdon, D Simon, J Wykes, T Phiri, P van der Gaag, M |
author_facet | Steel, C Korrelboom, K Fazil Baksh, M Kingdon, D Simon, J Wykes, T Phiri, P van der Gaag, M |
author_sort | Steel, C |
collection | OXFORD |
description | <p><strong>Background:</strong><br />
Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.</p><br />
<p><strong>Method:</strong><br />
Participants were aged 18–65 years old, had a clinical diagnosis of schizophrenia or schizoaffective disorder and at least a mild level of depression. Participants were randomly assigned (1:1) to receive PoMeT or treatment as usual. PoMeT was delivered in up to 12 individual sessions within 3 months. We stratified randomisation by site and by severity of depression using randomised-permuted blocks. Assessments were carried out at baseline, 3-month, 6-month and 9-month by assessors who were blind to treatment allocation. The primary outcome was reduction in the symptoms of depression at 3-month, 6-month and 9-month as measured by the BDI-II. Analysis was by intention-to-treat with linear mixed-effects models. The trial was registered with the ISRCTN registry number 99485756.</p><br />
<p><strong>Results:</strong><br />
One hundred participants were randomly assigned to either PoMeT (n = 49) or treatment as usual (n = 51). The reduction in BDI-II total score at 3 months was significantly greater for PoMeT than for treatment as usual (mean difference = 4.33, SE = 2.00, 95% CI 0.38 to 8.23; p = 0.03).</p><br />
<p><strong>Discussion:</strong><br />
To our knowledge this is, to date, the largest powered randomised controlled trial focused on the psychological treatment of depression in people diagnosed with schizophrenia. Results indicate that a brief targeted intervention can reduce the symptoms of depression in the group. The main limitation of the study is the lack of an active control group which may contribute to an inflated treatment effect.</p> |
first_indexed | 2024-03-07T07:20:22Z |
format | Journal article |
id | oxford-uuid:cc86a9d7-13bd-4e2e-ba91-4927ff1c4ba9 |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T07:20:22Z |
publishDate | 2020 |
publisher | Elsevier |
record_format | dspace |
spelling | oxford-uuid:cc86a9d7-13bd-4e2e-ba91-4927ff1c4ba92022-09-22T07:46:57ZPositive memory training for the treatment of depression in schizophrenia: A randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cc86a9d7-13bd-4e2e-ba91-4927ff1c4ba9EnglishSymplectic ElementsElsevier2020Steel, CKorrelboom, KFazil Baksh, MKingdon, DSimon, JWykes, TPhiri, Pvan der Gaag, M<p><strong>Background:</strong><br /> Around half of people diagnosed with schizophrenia suffer from co-morbid depression, yet there are no evidence-based psychological treatments to target this presentation.</p><br /> <p><strong>Method:</strong><br /> Participants were aged 18–65 years old, had a clinical diagnosis of schizophrenia or schizoaffective disorder and at least a mild level of depression. Participants were randomly assigned (1:1) to receive PoMeT or treatment as usual. PoMeT was delivered in up to 12 individual sessions within 3 months. We stratified randomisation by site and by severity of depression using randomised-permuted blocks. Assessments were carried out at baseline, 3-month, 6-month and 9-month by assessors who were blind to treatment allocation. The primary outcome was reduction in the symptoms of depression at 3-month, 6-month and 9-month as measured by the BDI-II. Analysis was by intention-to-treat with linear mixed-effects models. The trial was registered with the ISRCTN registry number 99485756.</p><br /> <p><strong>Results:</strong><br /> One hundred participants were randomly assigned to either PoMeT (n = 49) or treatment as usual (n = 51). The reduction in BDI-II total score at 3 months was significantly greater for PoMeT than for treatment as usual (mean difference = 4.33, SE = 2.00, 95% CI 0.38 to 8.23; p = 0.03).</p><br /> <p><strong>Discussion:</strong><br /> To our knowledge this is, to date, the largest powered randomised controlled trial focused on the psychological treatment of depression in people diagnosed with schizophrenia. Results indicate that a brief targeted intervention can reduce the symptoms of depression in the group. The main limitation of the study is the lack of an active control group which may contribute to an inflated treatment effect.</p> |
spellingShingle | Steel, C Korrelboom, K Fazil Baksh, M Kingdon, D Simon, J Wykes, T Phiri, P van der Gaag, M Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial |
title | Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial |
title_full | Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial |
title_fullStr | Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial |
title_full_unstemmed | Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial |
title_short | Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial |
title_sort | positive memory training for the treatment of depression in schizophrenia a randomised controlled trial |
work_keys_str_mv | AT steelc positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT korrelboomk positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT fazilbakshm positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT kingdond positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT simonj positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT wykest positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT phirip positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial AT vandergaagm positivememorytrainingforthetreatmentofdepressioninschizophreniaarandomisedcontrolledtrial |